La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Amphastar Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Amphastar Pharmaceuticals' Il CEO è Jack Zhang, nominato in Jan1996, e ha un mandato di 28.58 anni. la retribuzione annua totale è $ 7.72M, composta da 11.6% di stipendio e 88.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.8% delle azioni della società, per un valore di $ 105.11M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 10.8 anni e 5.2 anni.
Informazioni chiave
Jack Zhang
Amministratore delegato
US$7.7m
Compenso totale
| Percentuale dello stipendio del CEO | 11.6% |
| Mandato del CEO | 28.6yrs |
| Proprietà del CEO | 4.8% |
| Durata media del management | 10.8yrs |
| Durata media del Consiglio di amministrazione | 5.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio
May 13I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease
Apr 23Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$167m |
| Mar 31 2024 | n/a | n/a | US$155m |
| Dec 31 2023 | US$8m | US$898k | US$138m |
| Sep 30 2023 | n/a | n/a | US$135m |
| Jun 30 2023 | n/a | n/a | US$102m |
| Mar 31 2023 | n/a | n/a | US$93m |
| Dec 31 2022 | US$7m | US$1m | US$91m |
| Sep 30 2022 | n/a | n/a | US$77m |
| Jun 30 2022 | n/a | n/a | US$91m |
| Mar 31 2022 | n/a | n/a | US$81m |
| Dec 31 2021 | US$7m | US$898k | US$62m |
| Sep 30 2021 | n/a | n/a | US$36m |
| Jun 30 2021 | n/a | n/a | US$10m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$6m | US$898k | US$1m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$4m |
| Mar 31 2020 | n/a | n/a | US$52m |
| Dec 31 2019 | US$6m | US$898k | US$49m |
| Sep 30 2019 | n/a | n/a | US$52m |
| Jun 30 2019 | n/a | n/a | US$53m |
| Mar 31 2019 | n/a | n/a | US$2m |
| Dec 31 2018 | US$6m | US$1m | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$6m | US$880k | US$4m |
Compensazione vs Mercato: La retribuzione totale di Jack ($USD 7.72M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.62M ).
Compensazione vs guadagni: La retribuzione di Jack è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Jack Zhang (77 yo)
28.6yrs
Mandato
US$7,722,768
Compensazione
Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board | 28.6yrs | US$3.77m | 2.36% $ 53.6m | |
| Co-founder | 28.6yrs | US$7.72m | 4.8% $ 109.4m | |
| CFO, Executive VP of Finance | 10.3yrs | US$2.89m | 0.075% $ 1.7m | |
| Executive VP of Sales | 11.2yrs | US$1.78m | 0.096% $ 2.2m | |
| Senior EVP of Production & EVP of Scientific Affairs | 9.2yrs | US$2.03m | 0.38% $ 8.7m | |
| Senior Vice President of Human Resources & Corporate Communication | 2yrs | Nessun dato | Nessun dato | |
| Executive VP of Regulatory Affairs & Clinical Operations | no data | Nessun dato | Nessun dato |
10.8yrs
Durata media
65yo
Età media
Gestione esperta: Il team dirigenziale di AMPH è esperto e expertise (durata media dell'incarico 10.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman of the Board | 28.6yrs | US$3.77m | 2.36% $ 53.6m | |
| Co-founder | 28.6yrs | US$7.72m | 4.8% $ 109.4m | |
| CFO, Executive VP of Finance | 2yrs | US$2.89m | 0.075% $ 1.7m | |
| Executive VP of Sales | 2yrs | US$1.78m | 0.096% $ 2.2m | |
| Lead Independent Director | 22.5yrs | US$362.00k | 0.063% $ 1.4m | |
| Independent Director | 3.2yrs | US$330.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 5.2yrs | US$314.70k | 0.026% $ 600.8k |
5.2yrs
Durata media
65.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMPH sono considerati esperti (durata media dell'incarico 5.2 anni).